

EDUCATION AND POST-DOCTORAL TRAINING

- 2004-2006 Harold T. Shapiro Postdoctoral Fellowship in Bioethics, Princeton University Center for Human Values
2002-2004 Postdoctoral Fellow, National Institutes of Health, Department of Clinical Bioethics
1998-2003 D.Phil., Politics (political philosophy), Oxford University
1994-1998 MA, Philosophy, Hebrew University
1991-1994 BA, Philosophy and History, Tel Aviv University

ACADEMIC APPOINTMENTS

- 2019-Pres. Henry Rutgers Professor of Bioethics, at the Depts. of Philosophy (SAS) and Health Behavior and Social Policy (SPH); Founding Director, Center for Population-Level Bioethics (RBHS), Rutgers University
2019-Pres. Departmental Guest, Center for Human Values, Princeton University
2015-2019 Associate Professor, Dept. of Global Health and Population, Harvard TH Chan School of Public Health. Affiliated with the Concentration in Global Health and Health Policy, FAS, Harvard University; Harvard University Program in Ethics and Health (affiliated also with the Center for Bioethics, Harvard Medical School; Petrie-Flom Center, Harvard Law School; Secondary Concentration in Global Health and Health Policy, FAS; Center for Communicable Disease Dynamics, Harvard TH Chan School of Public Health)
2018 Visiting Professor, Department of Political Science, Hebrew University of Jerusalem
2014-2015 Associate Professor, Center for Bioethics, Harvard Medical School; Dept. of Global Health and Population, Harvard TH Chan School of Public Health, Harvard University Program in Ethics and Health
2012-2013 Associate Professor, Division of Medical Ethics, Dept. of Global Health and Social Medicine, Harvard Medical School; Harvard University Program in Ethics and Health
2008-2012 Assistant Professor, Division of Medical Ethics, Dept. of Global Health and Social Medicine, Harvard Medical School; Harvard University Program in Ethics and Health
2009-2010 Faculty Fellow, EJ Safra Foundation Center for Ethics, Kennedy School of Government, Harvard University
2006-2008 Instructor, Division of Medical Ethics, Dept. of Global Health and Social Medicine, Harvard Medical School; Harvard University Program in Ethics and Health

PEER-REVIEWED JOURNAL PUBLICATIONS * Corresponding author

1. Steuwer, B, & Eyal, N. (2023). Ethical and legal race-responsive vaccine allocation. *Bioethics*, 10.1111/bioe.13203. Advance online publication. <https://doi.org/10.1111/bioe.13203>
2. Eyal N. (2023). All research that might result in a pandemic must undergo external review. *Bioethics*, 37(3), 223–225. <https://doi.org/10.1111/bioe.13147>
3. Sjöstrand, M, & Eyal, N. (2023). The phantasm of zero suicide. *The British journal of psychiatry: the journal of mental science*, 222(6), 230–233. <https://doi.org/10.1192/bjp.2023.3>
4. Marsh AA, Magalhaes M, Peeler M, Rose SM, Darton TC, Eyal N, Morrison J, Shah SK, Schmit V. (2022). Characterizing altruistic motivation in potential volunteers for SARS-CoV-2 challenge trials. *PLoS One*.
5. Steuwer B, Eyal N, Magalhães M. (2022). Paired Publication: A Way to Lower One Barrier between Philosophical Insight and Bioethics. *Amer J of Bioeth.*; 22(12):33-5. [10.1080/15265161.2022.2134500](https://doi.org/10.1080/15265161.2022.2134500)
6. Takian A, Mousavi A, McKee M, Yazdi-Feyzabadi V, Labonté R, Tangcharoensathien V, Brugha R, Bradley E, Gostin L, Engebretsen E, Eyal N, Friel S, Rodwin VG, Norheim OF, Hajizadeh M, Ikegami N, Binagwaho A, Kickbusch I, Aryankhesal A, Haghdoost A-A. (2022). COP27: The Prospects and Challenges for the Middle East and North Africa (MENA). *Int J of Health Pol Mang.* www.ijhpm.com/article_4342.html.
7. Kahn R, Eyal N, Sow SO, Lipsitch M. (2022). Mass drug administration of azithromycin: an analysis. *Clinical Microbiology and Infection*. Published Oct 26, [10.1016/j.cmi.2022.10.022](https://doi.org/10.1016/j.cmi.2022.10.022).
8. Magalhaes M, Kuritzkes DR, Eyal N. (2022) The ethical case for placebo control in HIV-cure-related studies with ART interruption. *J of Viral Erad.* 8(3). Epub Aug 28. [10.1016/j.jve.2022.100084](https://doi.org/10.1016/j.jve.2022.100084); PMID: PMC9464947.
9. Bain LE, Berner-Rodoreda A, McMahan S, Sarker M, Tanser F, Bärnighausen, T, Wikler D, Eyal N (2022). One lesson of Covid-19: Conduct more health policy trials. *PNAS*, 119 (24), 1-4. [10.1073/pnas.211988711](https://doi.org/10.1073/pnas.211988711).
10. Eyal N, Gheaus A, Gosseries A, Magalhaes M, Ngosso T, Steuwer B, Tangcharoensathien V, Trifan I, Williams, A (2022). COVID vaccine prioritization in low-and middle-income countries may justifiably depart from high-income countries' age priorities. *CID*, ciac398, [10.1093/cid/ciac398](https://doi.org/10.1093/cid/ciac398).

11. Eyal N (2022). Research ethics and public trust in vaccines: the case of COVID-19 challenge trials. *J Med Ethics*, 0; 1-7. [10.1136/medethics-2021-108086](https://doi.org/10.1136/medethics-2021-108086).
12. Rohrig A, Eyal, N (2022). A new day for human challenge trials? *Trends in Molecul Med*. [10.1016/j.molmed.2022.05.002](https://doi.org/10.1016/j.molmed.2022.05.002).
13. Gerhard T, Strom B, Eyal N (2022). Pandemic vaccine testing: Combining conventional and challenge studies. *Pharmacoepidemiology and Drug Safety*, May 21. [10.1002/pds.5429](https://doi.org/10.1002/pds.5429).
14. Campbell JI*, Musiimenta A, Natukunda S, Eyal N, Haberer JE (2022). “The research assistants kept coming to follow me up; I counted myself as a lucky person”: Social support arising from a longitudinal HIV cohort study in Uganda. *PLoS One*. Jan 25;17(1):e0262989. [10.1371/journal.pone.0262989](https://doi.org/10.1371/journal.pone.0262989). PMID: 35077497. PMCID: [PMC8789171](https://pubmed.ncbi.nlm.nih.gov/PMC8789171/).
15. Berner-Rodoreda A*, McMahon S, Eyal N, Hossain P, Rabbani A, Barua M, Sarker M, Metta E, Mmbaga E, Leshabari M, Wikler D, Bärnighausen T. Consent Requirements for Testing Health Policies: An Intercontinental Comparison of Expert Opinions. *J Emp Res Hum Res Ethics*. (2022). Epub February 10. [10.1177/15562646221076764](https://doi.org/10.1177/15562646221076764).
16. Rohrig,* A, Eyal, N (2021). The Ethics of Human Challenge Trials Using Emerging SARS-CoV-2 Virus Variants, *J Infect Dis*, [jiab488](https://doi.org/10.1093/infdis/jiab488). [10.1093/infdis/jiab488](https://doi.org/10.1093/infdis/jiab488).
17. Berner-Rodoreda, A,* Bärnighausen, T, Eyal, N, et al (2021). “Thought provoking”, “interactive”, and “more like a peer talk”: testing the deliberative interview style in Germany. *SSM - Qualitative Research in Health* 2021;1 Epub 21 September. [10.1016/j.ssmqr.2021.100007](https://doi.org/10.1016/j.ssmqr.2021.100007)
18. Steuwer, B, Jamrozik, E, Eyal, N* (2021). Prioritizing second-generation SARS-CoV-2 vaccines through low-dosage challenge studies, *IJID*; Vol. 105; 307-311. [10.1016/j.ijid.2021.02.038](https://doi.org/10.1016/j.ijid.2021.02.038).
19. Eyal, N, Herlitz, A.* (2021). Input and output in distributive theory. *Noûs*. 1-23. [10.1111/nous.12392](https://doi.org/10.1111/nous.12392).
20. Eyal, N,* Lipsitch, M. (2021). Testing SARS-CoV-2 vaccine efficacy through deliberate natural viral exposure. *Clin Microb and Infect*, 27(3), 372–377. [10.1016/j.cmi.2020.12.032](https://doi.org/10.1016/j.cmi.2020.12.032).
21. Eyal N,* Gerhard T, Strom BL (2021). Strengthening and accelerating SARS-CoV-2 vaccine safety surveillance through registered pre-approval rollout after challenge tests. *Vaccine*. Jun 11;39(26):3455-3458. [10.1016/j.vaccine.2021.04.056](https://doi.org/10.1016/j.vaccine.2021.04.056). Epub 2021 Apr 30. PMID: 34023137; PMCID: [PMC8084609](https://pubmed.ncbi.nlm.nih.gov/PMC8084609/).
22. Eyal N,* Gerhard T. Do coronavirus vaccine challenge trials have a distinctive generalisability problem? *J Med Ethics*. 2021 Jun 7. [10.1136/medethics-2020-107109](https://doi.org/10.1136/medethics-2020-107109). Epub ahead of print. PMID: 34099541.
23. Lee K, Eyal N.* (2021) COVID-19 controlled human infection studies: worries about local community impact and demands for local engagement. *J Med Ethics*; 47:539-542. PMID: 33980657, PMCID: [PMC8117466](https://pubmed.ncbi.nlm.nih.gov/PMC8117466/). [10.1136/medethics-2021-107229](https://doi.org/10.1136/medethics-2021-107229).
24. Eyal N, Lipsitch, M (2021). How to Test Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines Ethically Even After One Is Available, *Clin Infect Dis*, 73(12), 2332-2334, [ciab182](https://doi.org/10.1093/cid/ciab182). [10.1093/cid/ciab182](https://doi.org/10.1093/cid/ciab182).
25. Eyal N, Herlitz A. (2021). Symposium: ethics of economic ordeals. *Econ and Phil*; 37(1), 1-7. [10.1017/S0266267120000292](https://doi.org/10.1017/S0266267120000292).
26. Broockman D, Kalla J, Guerrero A, Budolfson M, Eyal N, Jewell NP, Magalhaes M, and Sekhon JS. (2021). Broad Cross-National Public Support for Accelerated COVID-19 Vaccine Trial Designs. *Vaccine*, 39 (2): 309-316. [10.1016/j.vaccine.2020.11.072](https://doi.org/10.1016/j.vaccine.2020.11.072).
27. Rosa Diaz P, Darz A, Eyal N. (2020). COVID-19 Challenge Trials Would Save Lives And Avert Years In Poverty By Significant Margins, " *Health Affairs Blog*, [10.1377/hblog20201208.92114](https://doi.org/10.1377/hblog20201208.92114).
28. Eyal N, Holtzman L. (2020). Symposium on risks to by bystanders in clinical research: an introduction. *Bioeth*, 2020; 34:879–882. [10.1111/bioe.12830](https://doi.org/10.1111/bioe.12830).
29. Eyal N (2020). Is there an ethical upper limit on risks to study participants? *Pub Health Eth*, 1-14. [10.1093/phe/phaa028](https://doi.org/10.1093/phe/phaa028).
30. Eyal N (2020). Study bystanders and ethical treatment of study participants—A proof of concept. *Bioeth*. 00: 1-7. [10.1111/bioe.12825](https://doi.org/10.1111/bioe.12825).
31. Eyal N (2020). Rescuing vapers vs. rescuing smokers: the ethics. *Nicot & Tobacco Res*. [10.1093/ntr/ntaa157](https://doi.org/10.1093/ntr/ntaa157).
32. Eyal N, Lipsitch M. (2020). Opinion: It’s ethical to test promising coronavirus vaccines against less-promising ones. *PNAS* . [10.1073/pnas.2014154117](https://doi.org/10.1073/pnas.2014154117).
33. Steel R*, Buchak L, Eyal N. (2020). Why Continuing Uncertainties Are No Reason to Postpone Challenge Trials for Coronavirus Vaccines. *J Med Ethics*. [10.1136/medethics-2020-106501](https://doi.org/10.1136/medethics-2020-106501).
34. Eyal N,* Halkitis PN. (2020). AIDS activism and Coronavirus vaccine challenge trials. *AIDS and Behav* 24(12) 3302-3305; E-pub 26 June. [10.1007/s10461-020-02953-8](https://doi.org/10.1007/s10461-020-02953-8).
35. Eyal N (2020). Why Challenge Trials of SARS-CoV-2 Vaccines Could Be Ethical Despite Risk of Severe Adverse Events, *E&HR*, 42:1-11. [10.1002/eahr.500056](https://doi.org/10.1002/eahr.500056).
36. Eyal N*, Lipsitch M, Smith P. (2020). Human challenge studies to accelerate coronavirus vaccine licensure, *J Infect Dis*. E-pub 31 March. [10.1093/infdis/jiaa152](https://doi.org/10.1093/infdis/jiaa152); PMID: 32232474.
37. Eyal, N,* M Sjöstrand (2020). On Knowingly Setting Unrealistic Goals in Public Health. *Amer J of Pub Health* 110: 480-484. [10.2105/AJPH.2019.305428](https://doi.org/10.2105/AJPH.2019.305428).
38. Berner-Rodoreda A,* et al, including Eyal N. (2018). From doxastic to epistemic – a typology and critique of qualitative interview styles. *Qualitative Inquir*; 26(3-4), 291-305. [10.1177/1077800418810724](https://doi.org/10.1177/1077800418810724); PMID: 32038093 PMCID: [PMC6985996](https://pubmed.ncbi.nlm.nih.gov/PMC6985996/)

39. Kratka, A, et al. including **Eyal N.** (2019). HIV Cure Research: Risks Patients Expressed Willingness to Accept. *E&HR* 41, no. 6 23-34. [10.1002/eahr.500035](https://doi.org/10.1002/eahr.500035); PMID: 31743627
40. **Eyal N** & Magalhaes M. (2019). Is it ethical to isolate study participants to prevent HIV transmission during trials with an analytical treatment interruption? *J Infect Dis* 220(Supplement_1): S19–S21. [10.1093/infdis/jiz164](https://doi.org/10.1093/infdis/jiz164); PMID: 31264688 PMID: PMC6603965
41. **Eyal N**, et al. (2019). Regulating impact on bystanders in clinical trials: An unsettled frontier. *Clin Trials* 16(5): 450–454. [10.1177/1740774519862783](https://doi.org/10.1177/1740774519862783); PMID: 31368813 PMID: PMC6742522
42. **Eyal N** & Deeks SG. (2019). Risk to Nonparticipants in HIV Remission Studies With Treatment Interruption: A Symposium. *J Infect Dis* 220(Supplement_1): S1–S4. [10.1093/infdis/jiz173](https://doi.org/10.1093/infdis/jiz173); PMID: 31264687 PMID: PMC6603969
43. **Eyal N** (2019). How to Address the Risk of HIV Transmission in Remission Studies With Treatment Interruption: The Low-Hanging Fruit Approach. *J Infect Dis* 220(Supplement_1): S7–S11. [10.1093/infdis/jiz163](https://doi.org/10.1093/infdis/jiz163); PMID: 31264692 PMID: PMC6603962
44. **Eyal N** (2019). Removing One Barrier to Protecting Sex Partners in HIV Remission Studies With a Treatment Interruption. *J Infect Dis* 220(Supplement_1): S22–S23. [10.1093/infdis/jiz162](https://doi.org/10.1093/infdis/jiz162); PMID: 31264690 PMID: PMC6603972
45. **Eyal N** (2019). Risk to bystanders in clinical trials: A symposium. *Clin Trials* 16(5): 447–49. [10.1177/1740774519862758](https://doi.org/10.1177/1740774519862758); PMID: 31368795 PMID: PMC6742523
46. **Eyal N**, & Wikler D (2019). Ethical complexities of responding to bystander risk in HIV prevention trials. *Clinical Trials*, 16(5),458–460. [10.1177/1740774519862765](https://doi.org/10.1177/1740774519862765)
47. Murray BR, Kratka A, Scherr KA, **Eyal N**, Blumenthal-Barby J, Freedburg K, Kuritzkes DR, Hammitt JK, Edifor R, Katz MN, Pollak KI, Zikmund-Fisher BJ, Halpern SD, Barks MC, Ubel PA, (2019). What Risk of Death Would People Take to be Cured of HIV, and Why? A Survey of People Living With HIV. *J Virus Education*, 5(2):109–115 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543487>.
48. Zhang Y*, Bärnighausen T, **Eyal N** (2019). When Global ART Budgets Cannot Cover All Patients, Who Should Be Eligible? *JAIDS*. E-Pub: 25 February. [10.1097/QAI.0000000000002017](https://doi.org/10.1097/QAI.0000000000002017). PMID: 30839381 PMID: PMC6522313
49. Ng JWL*, Sjöstrand M, **Eyal N** (2019). Adding Lithium to Drinking Water for Suicide Prevention—the Ethics. *Pub Health Eth.* E-Pub: 12 February. [10.1093/phe/phz002](https://doi.org/10.1093/phe/phz002).
50. Berner-Rodoreda A*, et al, including **Eyal N** (2018). From doxastic to epistemic—a typology and critique of qualitative interview styles. *Qualitat Inquiry*. E-Pub: 28 November. [10.1177/10777800418810724](https://doi.org/10.1177/10777800418810724).
51. International Panel on Social Progress (IPSP), incl. **Eyal N** *Rethinking Society for the 21st Century (IPSP 2018 report)*. New York: Cambridge UP (2018). In three volumes. I contributed to the chapter on health.
52. Campbell JI*, Haberer JE, Musiimenta A, **Eyal N** (2018). Dependence on digital medicine in resource-limited settings. *Am J Bioeth*; 18(9): 54–56. E-Pub 20 September. [10.1080/15265161.2018.1498949](https://doi.org/10.1080/15265161.2018.1498949); PMID: 30265607 PMID: PMC6203887.
53. **Eyal N***, Lipsitch M, Bärnighausen T, Wikler D (2018). Risk to study nonparticipants: a procedural approach. *PNAS* 115(32):8051–53. [10.1073/pnas.1810920115](https://doi.org/10.1073/pnas.1810920115); PMID: 30087210 PMID: PMC6094093.
54. Swanson KC* et al, incl. **Eyal N** (2018). Contact tracing performance during the Ebola epidemic in Liberia, 2014–2015. *PLoS Negl Trop Dis*; 12(9):e0006762. [10.1371/journal.pntd.0006762](https://doi.org/10.1371/journal.pntd.0006762); PMID: 30208032 PMID: PMC6152989.
55. Brown R*, Deeks S, **Eyal N** 2018, Maximizing the global health impact of future HIV cure-related interventions through advance planning. *J Virus Erad*; 4(3):182–185. <https://www.ncbi.nlm.nih.gov/pubmed/30050682>; PMID: 6038126.
56. Kahn R*, Rid A, **Eyal N**, et al. (2018). Choices in vaccine trial design in epidemics of emerging infections. *PLoS Medicine*; 15(8). [10.1371/journal.pmed.1002632](https://doi.org/10.1371/journal.pmed.1002632); PMID: 30086139 PMID: PMC6080746.
57. **Eyal N***, Holtzman LG, Deeks S (2018). Ethical issues in HIV remission trials. *Curr Opin HIV AIDS*; 13(5):422–427. [10.1097/COH.0000000000000489](https://doi.org/10.1097/COH.0000000000000489).
58. Campbell J*, **Eyal N**, Musiimenta A et al. (2018). Ugandan study participants experience electronic monitoring of antiretroviral therapy adherence as welcomed pressure to adhere. *AIDS Behav*; 1–10. [10.1007/s10461-018-2200-8](https://doi.org/10.1007/s10461-018-2200-8); PMID: 29926301 PMID: PMC6309333.
59. **Eyal N***, Romain P, Robertson C. Can rationing through inconvenience be ethical? *Hastings Ctr Rpt*; 48(1):10–22. [10.1002/hast.806](https://doi.org/10.1002/hast.806); PMID: 29457241.
60. **Eyal N***, Holtzman L (2018). Invited commentary on Dubé et al. (Perceptions of equipoise, risk/benefit ratios, and “otherwise healthy volunteers” in the context of early-phase HIV cure research in the United States—a qualitative inquiry): Are HIV-infected candidates for participation in risky cure-related studies otherwise healthy? *J Empir Res Hum Res Ethics*, 13(1):18-22. [10.1177/1556264617740244](https://doi.org/10.1177/1556264617740244); PMID: 29179624 PMID: PMC6103447.
61. **Eyal N*** (2018). What can the lived experience of participating in risky HIV cure-related studies establish? *J Med Ethics*; 44(4):277–278. [10.1136/medethics-2017-104593](https://doi.org/10.1136/medethics-2017-104593); PMID: 29321219 PMID: PMC6093613.
62. Wu F, Zhang A, Babbitt A, Ma Q, **Eyal N***, Pan X, Cai W, Hu F, Cheng Y, Tucker JD (2017). Overcoming HIV stigma? A qualitative analysis of HIV cure research and stigma among men who have sex with men living with HIV. *Arch Sex Behav*; 47(7):2061–2069. [10.1007/s10508-017-1062-x](https://doi.org/10.1007/s10508-017-1062-x); PMID: 29149399 PMID: PMC5957764.
63. Lipsitch M*, **Eyal N** (2017). Improving vaccine trials in infectious disease emergencies. *Science*; 357(6347):153–6. [10.1126/science.aam8334](https://doi.org/10.1126/science.aam8334); PMID: 28706038 PMID: PMC5568786.
64. Dickert N*, **Eyal N**, et al. (2017). Re-framing consent for clinical research: A function-based approach. *Amer J of Bioethics*; 17(12):3-11, with an editorial by T. Beauchamp. [10.1080/15265161.2017.1388448](https://doi.org/10.1080/15265161.2017.1388448); PMID: 29148951

65. Richardson HS, **Eyal N**, Campbell J et al. (2017). When ancillary care would compromise study aims. *N Engl J Med*; 377(13): 1213–1215. [10.1056/NEJMp1702651](https://doi.org/10.1056/NEJMp1702651).
66. Voorhoeve AE, et al, including **Eyal N** (2017). Making fair choices on the path to universal health coverage: Applying principles to difficult cases. *Health Systems & Reform*; 301–312. [10.1080/23288604.2017.1324938](https://doi.org/10.1080/23288604.2017.1324938); PMID: 30359178
67. **Eyal N** (2017). Afterword: Returning to philosophical foundations in research ethics. *J Med Ethics*; 43(2):132–133. [10.1136/medethics-2016-103429](https://doi.org/10.1136/medethics-2016-103429); PMID: 27354247 PMID: PMC5191995.
68. **Eyal N** (2017). The benefit/risk ratio challenge in clinical research, and the case of HIV cure: an introduction. *J Med Ethics*; 43:65–66. [10.1136/medethics-2016-103427](https://doi.org/10.1136/medethics-2016-103427); PMID: 27215763 PMID: PMC5121082.
69. **Eyal N** (2017). How to keep high-risk studies ethical: classifying candidate solutions. *J Med Ethics*; 43(2):74–77. [10.1136/medethics-2016-103428](https://doi.org/10.1136/medethics-2016-103428); PMID: 27288098 PMID: PMC5148732.
70. **Eyal N***, Lipsitch M (2017). Vaccine testing for emerging infections: the case for individual randomisation. *J Med Ethics*; 43(9):625–631. [10.1136/medethics-2015-103220](https://doi.org/10.1136/medethics-2015-103220); PMID: 28396558 PMID: PMC5577361.
71. **Eyal N***. Tieffenbach E (2017). Incommensurability and trade. *The Monist*; 99(4):387–405. [10.1093/monist/onw012](https://doi.org/10.1093/monist/onw012)
72. Voorhoeve AE* et al, incl. **Eyal N** (2016). Three case studies in making fair choices on the path to universal health coverage. *Health Hum Rights*; 18(2):11–22. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395011/>.
73. **Eyal N***, Cancedda C, Hurst SA., Kyamanywa P (2017). Coordinating between medical professions' tasks to optimize sub-Saharan health systems: a response to recent commentaries. *Int J Health Policy Manag*; 6(2):123–125. [10.15171/ijhpm.2016.142](https://doi.org/10.15171/ijhpm.2016.142); PMID: 28812790 PMID: PMC5287930.
74. Deeks SG* et al, incl. **Eyal N** (2016). International AIDS Society global scientific strategy: towards an HIV cure. *Nat Med*; 22(8):839–850. [10.1038/mm.4108](https://doi.org/10.1038/mm.4108); PMID: 27400264 PMID: PMC5322797.
75. Healy J*, Hope R, Bhabha J, **Eyal N** (2016). Paying for antiretroviral adherence: is it unethical when the patient is an adolescent? *J Med Ethics*; 43(3):135–136. [10.1136/medethics-2015-103359](https://doi.org/10.1136/medethics-2015-103359); PMID: 27645199.
76. Emhoff IA, Fugate E, **Eyal N*** (2016). Is there a moral right to nonmedical vaccine exemption? *Am J Law Med*; 42: 598–620. [10.1177/0098858816658281](https://doi.org/10.1177/0098858816658281); PMID: 29086637.
77. Zimmerman M,* Shah S, Shakya R, Chansi BS, Shah K, Munday D, **Eyal N** & Hayes B (2016). Improving performance in Nepal's rural hospitals through a 'bundled' program of human resource support. *WHO Bulletin* 94 [10.2471/BLT.15.153619](https://doi.org/10.2471/BLT.15.153619); PMID: 26769998 PMID: PMC4709798.
78. **Eyal N***, Cancedda C, Kyamanywa P, Hurst SA. (2016). Non-physician clinicians in sub-Saharan Africa and the evolving role of physicians. *Int J Health Policy Manag* 5: 1–5. With responses by Binagwaho et al, Cubaka et al, Dovlo et al, Dussault & Cobb, Monekosso, Olapade-Olaopa et al, and Sidat. [10.15171/ijhpm.2015.215](https://doi.org/10.15171/ijhpm.2015.215); PMID: 26927585 PMID: PMC4770920.
79. Campbell JI, **Eyal N***, Musimenta A, Haberer J (2016). Ethical questions in medical electronic adherence monitoring. *J Gen Int Med*; 31(3):338–342. [10.1007/s11606-015-3502-4](https://doi.org/10.1007/s11606-015-3502-4); PMID: 26358284 PMID: PMC4762813.
80. Bärnighausen T*, **Eyal N**, Wikler D (2015). HIV treatment-as-prevention research: authors' reply. *PLoS Med*; 12(3): [10.1371/journal.pmed.1001799](https://doi.org/10.1371/journal.pmed.1001799); PMID: 25756214 PMID: PMC4355408.
81. **Eyal N** (2015). Inequality in political philosophy and epidemiology: a remarriage. *J Applied Philosophy*; 35(1). [10.1111/japp.12150](https://doi.org/10.1111/japp.12150).
82. Murthi S*, **Eyal N**, Norheim OF, Ruan DT, Ntakiyiruta G, Riviello R (2015). Standard of care vs. second-best: Ethical dilemmas in surgery for high risk papillary thyroid cancer in low and middle-income countries. *J Canc Pol*; 6:8–10. [10.1016/j.jcpo.2015.08.006](https://doi.org/10.1016/j.jcpo.2015.08.006).
83. **Eyal N** (2015). Informed consent to participation in interventional studies: second-order in a different sense. *J Law Biosci*; 2(1):123–128. [10.1093/jlb/lsv001](https://doi.org/10.1093/jlb/lsv001); PMID: 27774189 PMID: PMC5033560.
84. Lipsitch M,* **Eyal N**, Halloran E, Hernán MA, Longini IM, Perencevich, EN, Grais RF* (2015). Vaccine testing: Ebola and beyond. *Science Magazine*; 348(6230):46–48. [10.1126/science.aaa3178](https://doi.org/10.1126/science.aaa3178); PMID: 25838371 PMID: PMC4408019.
85. **Eyal N** (2015). Nudge, embarrassment, and restriction—replies to Voigt, Tieffenbach, and Saghai. *Int J Health Policy Manag*; 4(1):53–54. [10.15171/ijhpm.2015.01](https://doi.org/10.15171/ijhpm.2015.01); PMID: 25584355 PMID: PMC4289039.
86. Ottersen T, Norheim OF* (2014). On behalf of the World Health Organization Consultative Group on Equity and Universal Health Coverage, including **Eyal N** Making fair choices on the path to universal health coverage. *Bulletin of the World Health Organization*; 92:389. [10.2471/BLT.14.139139](https://doi.org/10.2471/BLT.14.139139); PMID: 24940009 PMID: PMC4047814.
87. **Eyal N** (2014). Pediatric heart surgery in Ghana: Three ethical questions. *J Clin Ethics*; 25(4):317–23. PMID: 25517570.
88. **Eyal N** (2014). Non-consequentialist utilitarianism. *Revue Éthique et Économique*; 11(2):34–53 <http://hdl.handle.net/1866/10932>.
89. **Eyal N** (2014). Two kinds of to-kind benefits and other reasons why shared vulnerability can keep clinical studies ethical. *Amer J Bioethics*; 14(12):22–24. [10.1080/15265161.2014.964880](https://doi.org/10.1080/15265161.2014.964880); PMID: 25369411.
90. **Eyal N** (2014). Nudging by shaming, shaming by nudging. *Int J Health Policy Manag*; 3:1–4. [10.15171/ijhpm.2014.68](https://doi.org/10.15171/ijhpm.2014.68)
91. Bärnighausen T*, **Eyal N**, Wikler D (2014). HIV Treatment-as-prevention at a crossroads. *PLoS Medicine*; 11: e1001654. [10.1371/journal.pmed.1001654](https://doi.org/10.1371/journal.pmed.1001654); PMID: 24892694 PMID: PMC4043489.
92. **Eyal N**, Kuritzkes D* (2014). Challenges in clinical trial design for HIV cure research. *Lancet*; 382:1464–1465. [10.1016/S0140-6736\(13\)62040-1](https://doi.org/10.1016/S0140-6736(13)62040-1); PMID: 24182529.

93. Eyal N 2013. Paternalism, French fries and the weak-willed Witness. *J Med Ethics*; 40:353–354. [10.1136/medethics-2013-101555](https://doi.org/10.1136/medethics-2013-101555); PMID: 24335857.
94. Wikler D, Eyal N* (2013). Nudges and noodges: the ethics of health promotion—New York style. *Pub Health Eth.*; 3(6): 233–234. [10.1093/phe/pht033](https://doi.org/10.1093/phe/pht033).
95. Eyal N (2013). Sticking with carrots and sticks (sticking points aside): A response to Ventakapuram, Goldberg, and Forrow. *International J of Health Policy & Management*; 1:317–318. [10.15171/ijhpm.2013.64](https://doi.org/10.15171/ijhpm.2013.64); PMID: 24596892 PMID: PMC3937905.
96. Eyal N (2013). Denial of treatment to obese patients—the wrong policy on personal responsibility for health. *Int J Health Policy Manag*; 1(2):Article 5; 107–110. [10.15171/ijhpm.2013.18](https://doi.org/10.15171/ijhpm.2013.18); PMID: 24596846 PMID: PMC3937915.
97. Eyal N,*(2013). Gosseries A Obamacare and conscientious objection: some introductory thoughts. *Eth Pers*; 20(1):109–117
98. Eyal N, Firth P*(2012). MGH Disaster Relief Ethics Group. Repeat triage in disaster relief: questions from Haiti. *PLoS Currents Disasters*; 1–8. [10.1371%2F4fbbdec6279ec](https://doi.org/10.1371%2F4fbbdec6279ec).
99. Zimmerman M,* Shakya R, Pokhrel BM, Eyal N, Rijal BP, Shrestha RN, Sayami A (2012). Medical students' characteristics as predictors of career practice location: retrospective cohort study tracking graduates of Nepal's first medical college. *BMJ*; 345:e4826. [10.1136/bmj.e4826](https://doi.org/10.1136/bmj.e4826); PMID: 22893566 PMID: PMC3419272.
100. Eyal N (2014). Using informed consent to save trust. *J Med Ethics*; 40:437–444. [10.1136/medethics-2012-100490](https://doi.org/10.1136/medethics-2012-100490); PMID: 25180355.
101. Eyal N*, Bärnighausen T (2012). Precommitting to serve the underserved. *Am J Bioeth*; 12(5):23–34. [10.1080/15265161.2012.665134](https://doi.org/10.1080/15265161.2012.665134); PMID: 22548519 PMID: PMC4300339.
102. Eyal N (2012). Reconciling informed consent with prescription drug requirements. *J Med Ethics*; 38(10):589–591. [10.1136/medethics-2012-100667](https://doi.org/10.1136/medethics-2012-100667); PMID: 22865927.
103. Eyal N (2012). Grounding public reasons in rationality: The conditionally-compassionate medical student and other challenges. *Law & Ethics of Human Rights*; 6(1):48–68. [10.1515/1938-2545.1067](https://doi.org/10.1515/1938-2545.1067).
104. Eyal N (2011). Why treat noncompliant patients? Beyond the decent minimum account. *J Med Phil*; 36(6):572–588. [10.1093/jmp/jhr051](https://doi.org/10.1093/jmp/jhr051); PMID: 22185704.
105. Eyal N*, Voorhoeve AE (2011). Inequalities in HIV care: chances versus outcomes. *Amer J of Bioeth* 2011; 11(12):42–44. [/10.1080/15265161.2011.615890](https://doi.org/10.1080/15265161.2011.615890).
106. Bitton A, Eyal N* (2011). Too poor to treat? The complex ethics of cost-effective tobacco control. *Pub Health Eth*; 4(2):109–120. [10.1093/phe/phr014](https://doi.org/10.1093/phe/phr014).
107. Eyal N*, Hurst SA (2011). Scaling up changes in doctors' education for rural retention: a comment on World Health Organization recommendations. *Bulletin of the World Health Organization*; 89(2):83.
108. Eyal N (2010). Near-universal basic income. *Basic Income Studies*; 5(1):1–26. [10.2202/1932-0183.1149](https://doi.org/10.2202/1932-0183.1149)
109. Sofaer N*, Eyal N (2010). Translational research beyond approval: A two-stage ethics review. *Amer J of Bioeth*; 10: W1–3. [10.1080/15265161.2010.500199](https://doi.org/10.1080/15265161.2010.500199); PMID: 20694895.
110. Sofaer N*, Eyal N (2010). The diverse ethics of translational research. *Amer J of Bioeth*; 10(8), with seven responses: 19–30. [10.1080/15265161.2010.494214](https://doi.org/10.1080/15265161.2010.494214); PMID: 20694901.
111. Eyal N (2009). Is the Body Special? Article-length essay—C. Fabre, Whose body is it anyway? *Utilitas*; 21(2): 233-45. [10.1017/S0953820809003513](https://doi.org/10.1017/S0953820809003513).
112. Eyal N, Hurst SA (2008). Physician brain drain—can nothing be done? *Public Health Ethics*; 1(2):180-192. [10.1093/phe/phn026](https://doi.org/10.1093/phe/phn026).
113. Eyal N (2008). Utilitarianism and coercion. *Notizie di Politeia*; 24(90):108-123.
114. Eyal N (2007). Egalitarian justice and innocent choice. *JESP*; 2(1):1–18. <https://heinonline.org/HOL/P?h=hein.journals/jetshy2&i=1>.
115. Eyal N (2006). If you're an egalitarian, how come you're so *inegalitarian* about your body? *Iyyun*; 55:299–309. www.jstor.org/stable/23354444.
116. Eyal N (2005). Perhaps the most important primary good: Self-respect and Rawls's principles of justice. *Politics, Philosophy, and Economics*; 4(2):195–219. [10.1177%2F1470594X05052538](https://doi.org/10.1177%2F1470594X05052538).

PEER-REVIEWED ENCYCLOPEDIA ENTRIES AND CHAPTERS

1. Eyal N (forthcoming 2023). On prevalence and prudence. In: Davies B, Marco Gd, Savulescu J, Levy N (eds.), *Responsibility and Healthcare*. Oxford: Oxford UP.
2. Eyal N (2023). Utilitarianism and Research Ethics. In: MacAskill W, Meissner D, Chappell R (eds.), *Introduction to Utilitarianism: An Online Textbook* [Utilitarianism.net]. Oxford.
3. Eyal N (2023). Ethical Issues in Disaster Medicine. In: Ciottone GR (ed.), *Disaster Medicine* (chapter 11). 2nd ed. Elsevier: Philadelphia, PA: Elsevier; 2016: 67-74. Substantially revised 3rd edition.
4. Eyal N (2022). Research during Pandemics and Epidemics. In: Iltis AS, MacKay D (eds), *The Oxford Handbook of Research Ethics*: Oxford University Press. [10.1093/oxfordhb/9780190947750.013.34](https://doi.org/10.1093/oxfordhb/9780190947750.013.34).

5. **Eyal N**, Magalhaes M. (2021). The functions of informed consent. In: Bankert EA, Gordon BG, Hurley EA, eds., *Institutional Review Board: Management and Function: Management and Function*, 3rd Edition. Burlington MA: Jones & Bartlett.
6. **Eyal N**, SA Hurst, CJL Murray, SA Schroeder and D Wikler (2020). Introduction: Philosophy and the Global Burden of Disease Study. *Measuring the Global Burden of Disease*. N Eyal, SA Hurst, CJL Murray, SA Schroeder and D Wikler. New York: Oxford UP.
7. **Eyal N**. (2020). Measuring Health-State Utility via Cured Patients. *Disability, Health, Law, and Bioethics*. Ed. by I G Cohen, C Shachar, A Silvers and M A Stein. New York: Cambridge UP; 266–279.
8. **Eyal N** (2019). Informed consent. *Stanford Encyclopedia of Philosophy*. Substantially revised 2019 (originally published 2011). <http://plato.stanford.edu/entries/informed-consent/>. As of September 28, 2016, downloaded 39,574 times during the preceding full academic year
9. **Eyal N** (2015). Concentrated risk, the Coventry Blitz, Chamberlain’s cancer. In: Cohen IG, N Daniels, N Eyal, eds. *Identified vs Statistical Persons*. New York: Oxford UP
<https://www.researchgate.net/deref/http%3A%2F%2Fdx.doi.org%2F10.1093%2Facprof%3Aoso%2F9780190217471.003.0007>
10. Cohen* IG, Daniels N, **Eyal N**. (2015). Introduction. In our (eds). *Identified vs statistical lives*. New York: Oxford UP
11. **Eyal N**, Hurst SA*. (2014). Do Health Workers have a Duty to Work in Underserved Areas? In: Arras JD, Fenton E, Kukla R, eds. *The Routledge Companion to Bioethics*. New York: Routledge, 114–32. <https://archive-ouverte.unige.ch/unige:73009>
12. **Eyal N** (2014). The Regulation of risk: an introduction. In IG Cohen & H Fernandez Lynch, eds., *The Future of Human Subjects Research Regulation*. Cambridge, Mass.: MIT Press, 27–29
13. **Eyal N***, Bärnighausen T. (2013). Conditioning medical scholarships on long, future service: a defense. I. G. Cohen, ed, *The Globalization of Health Care: Legal and Ethical Challenges*. New York: Oxford UP
14. **Eyal N** (2012). Global health impact labels. In E Emanuel, J Millum, eds, *Global Justice & Bioethics*. Oxford UP
15. Lippert-Rasmussen K*, **Eyal N** (2012). Equality and egalitarianism. In R Chadwick, ed., *Encyclopedia of Applied Ethics*, 2nd Edition, Vol. 2. San Diego: Academic Press, 141–48. [10.1016/B978-0-12-373932-2.00305-7](https://doi.org/10.1016/B978-0-12-373932-2.00305-7)
16. **Eyal N** (2013). Leveling down health. In N Eyal, OF Norheim, SA Hurst, and D Wikler, eds, *Inequalities in Health: Concepts, Measures, and Ethics*. New York: Oxford UP, 194–213
17. **Eyal N**, Norheim OF*, Hurst SA, Marchand S, Wikler D. (2013). Inequalities and Inequities in Health. In N Eyal, O Norheim, SA Hurst, and D Wikler, eds, *Inequalities in Health: Concepts, Measures, and Ethics*. New York: Oxford UP, 1–10
18. **Eyal N** Hurst S. A. Coercion in the fight against medical brain drain. R Shah, ed, (2010). *The International Migration of Health Workers: Ethics, Rights and Justice*. London: Palgrave MacMillan, 137–158. [10.1057/9780230307292_10](https://doi.org/10.1057/9780230307292_10)
19. **Eyal N** (2007). Poverty reduction and equality with strong incentives: the brighter side of false needs. In: J Ryberg, TS Petersen & C Wolff (eds.), *New Waves in Applied Ethics*. London: Palgrave-MacMillan:182–216

PEER-REVIEWED EDITED VOLUMES (the full CV lists also several edited peer-reviewed journal symposia)

20. **Eyal N**, SA Hurst, CJL Murray, SA Schroeder and D Wikler, eds. (2020). *Measuring the Global Burden of Disease*. Population-Level Bioethics. New York: Oxford UP
21. Cohen IG, Daniels N, **Eyal N**, eds. (2015). *Identified vs. Statistical Persons*. New York: Oxford UP
22. **Eyal N**, Norheim OF, Hurst SA, Wikler D, eds. (2013). *Inequalities in Health: Concepts, Measures, and Ethics*. Oxford UP

A BOOK-LENGTH WHO REPORT

23. Consultative Group, incl. **Eyal N** (2014). *Making Fair Choices on the Path to Universal Health Coverage—Final Report of the WHO Consultative Group on Equity and UHC*. Geneva: WHO. French and Spanish editions: 2015.
www.who.int/publications/i/item/9789241507158.

LETTERS

24. **Eyal N** (2022). Longtermists should take climate change very seriously. *EA Forum*. Oct 3.
<https://forum.effectivealtruism.org/posts/iWH4oxaHmfRgSSTcm/longtermists-should-take-climate-change-very-seriously>.
25. Steuwer B, Eyal N. SARS-CoV-2 Human Challenge Studies. *N Engl J Med*. 2021 Sep 29;10.1056/NEJMc2113574#sa1.
[10.1056/NEJMc2113574](https://doi.org/10.1056/NEJMc2113574). Epub ahead of print. PMID: 34587380.
26. **Eyal N***, Caplan A, Plotkin S, (2021). COVID vaccine efficacy against the B.1.351 (“South African”) variant-The urgent need to lay the groundwork for possible future challenge studies. *Hum Vaccin Immunother*. Apr 27:1-2. Epub ahead of print. PMID: 33905309.
27. **Eyal N** (2020). Unnecessary hesitancy on human vaccine tests. *Science* 369(6500): 150-151.
28. **Eyal N**, Lipsitch M, Smith PG (2020). Response to Hasford and to Spinola et al. *J Infect Dis.*;222, (9),’1574–1575.
[10.1093/infdis/jiaa458](https://doi.org/10.1093/infdis/jiaa458).
29. **Eyal N**, Lipsitch M, Smith PG. (2020). Response to Dawson et al. *J Infect Dis*. E-pub 4 June, [10.1093/infdis/jiaa315](https://doi.org/10.1093/infdis/jiaa315)
30. **Eyal N**, Lipsitch M, Smith PG. (2020). Response to Cioffi. *J Infect Dis.*; 222(1):169-170. [10.1093/infdis/jiaa217](https://doi.org/10.1093/infdis/jiaa217)
31. Firth P, **Eyal N**. (2020). Allocating Medical Resources in the Time of Covid-19. *N Engl J Med.*; 382(22):e79.
[10.1056/NEJMc2009666](https://doi.org/10.1056/NEJMc2009666), PMID: 32343501

32. Zhang, Y*, Bärnighausen T, Eyal N (2019). Reply. *JAIDS* 82(2): e41. [10.1097/QAI.0000000000002127](https://doi.org/10.1097/QAI.0000000000002127); PMID: 31513077
PMCID: PMC6749966

INVITED LECTURES, CONFERENCE LECTURES: Full CV lists 110 international, 45 national, 15 regional, many local talks.

TEACHING, TRAINING, AND CONSULTING (on full CV, including repeat consultations to WHO, PAHO, IPSP, IHME...).

MEDIA INTERVIEWS: A frequent commentator, who gave a *TED* talk, *Guardian*, *NYT*, *Washington Post*, *Bloomberg*, *CNN*, *CNBC*, and many other leading newspapers, TV and radio stations, and other media around the world.

CURRENT FUNDING

- 2022-2023 *Longtermist biosecurity*. Longview Foundation 2039320. Role: PI, Award: \$932,611.
2020-2021 *RAPID: Responsible conduct of accelerated SARS-CoV-2 vaccine research through challenge trials*. National Science Foundation 2039320. Role: PI, Award: \$200,000.
2019-2020 *Bioethical issues research supplement to Physicians' Perceptions, Attitudes, and Communication of E-cigarettes (PACE)*-3R01CA190444-05S1 from National Cancer Institute. (Role: Co-Investigator, C. Delnevo PI). Award (\$89,533(D)/\$142,357(T))
2017-2020 *Health policy trials: method, voice, and ethics*. Wellcome 208766/Z/17/Z - PI (with T. Bärnighausen, M. Leshabari, M. Sarker, D. Wikler), Euro 900,000 in total.
2015-2020 *HIV cure studies: risk, risk perception, and ethics*. NIAID - 1 R01 AI114617-01A1. PI, \$1,405,705 (+ 2 x NCE).

PAST FUNDING (full CV also lists past funding from *CIHR*, *Brocher*, *Safra Center*, *Harvard Global Health Institute*, and *NORAD*)

- 2016-2017 Supplement grant for the latter (NIAID 3R01AI114617-03S1). Total funding: \$86,027 (Direct Costs: \$70,652; Indirect Costs: \$15,375). PI. For Brandon Brown. Currently awaiting NIH response on Year 2 funding.
2016-2019 *Development Initiative for Ethical Review and Oversight of Health Research Involving Human Subjects in Rwanda*. Fogarty – 1R25 TW010298-01. PI (with Bern Friedland), \$1,218,293 when the project was planned for a 2021 end-date. Budget given an updated (May 2019) end-date is still pending.
2014-2015 *HIV cure studies: risk, risk perception, and ethics*. NIAID - 1 R56 AI114617-01. PI, \$527,747 (R01 bridge funding).
2013-2015 *The Ethics of Electronic Adherence Monitoring for HIV Research and Care in Uganda*. NIH/NIAID - R21 AI108329-01. PI (with Jessica Haberer), \$417,746.

HONORS & PRIZES

- 2018 Lady Davis Fellowship, Hebrew University of Jerusalem.
2014 Nominated for the Donald O'Hara Faculty Prize for Excellence in Teaching, Harvard Medical School
2013 Certificate of excellence in tutoring, Harvard Med. Sch.; Rector Award, Roskilde U, Denmark; LS Rockefeller Fellowship, Princeton U. Ctr for Human Values (forwent to focus on work at HMS).
2011 Academics Stand Against Poverty (ASAP) Award, MacMillan Center, Yale University
2010 Mark S. Ehrenreich Prize in Healthcare Ethics Research, University of S. California and the International Association of Bioethics, for the best paper at the IAB 2010 Congress.
2009 Edmund J. Safra Fellowship in Ethics
2006 Young Scholar Award, Ethics and Public Life Program, Cornell University
2003 Nominated by Oxford University for the Barker Prize, Political Studies Association
2002 Barbinder-Watson Fund Prize, St. Hugh's College, Oxford University
2001 Scatcherd Scholarship, Oxford University
2000 Anglo-Israel Association Prize
1999 Anglo-Jewish Association Prize; Karten Prize, Ian-Karten Trust; AVI Prize, AVI Institute; Larkinson Scholarship in Politics, St. Hugh's College, Oxford U.; Wingate Harold Hyam Foundation Award.
1998 Lavon Prize for research on labor issues, Lavon Institute for Labour Movement Research, Israel; HaEzrahi Prize for outstanding MA student, Hebrew U. Dept. of Philosophy
1994 Outstanding BA student award, Tel Aviv U. Department of History

A SELECTION OF CONFERENCES ORGANIZED (The full CV states many others)

- 2018 Co-organizer: Ordeals for health: Ethics and efficient delivery (Safra Center, HSPH, HMS, HLS, HKS, Wellcome)
2017 Co-organizer: Efficacy testing of vaccines for infectious disease outbreaks funding (Ethox)
2017 Organizer: Risk to nonparticipants in medical research: the ethics (NIAID)
2010,2,4,6,8 Co-organizer: five summer schools: Brocher Summer Academy in Population-Level Bioethics.
2012-2013 Co-organizer: Three workshops for the WHO workgroup on *Equity Considerations in the WHO Action Plan on Financing Universal Coverage* – in Norway, Switzerland, and the US (NORAD, IDRC, Swiss NSF, Brocher)

- 2012 Co-organizer, *Egalitarianisms: Current Debates on Equality/Priority in Health, Wealth, Welfare* (McGill, CIHR)
 2009-2012 Co-organizer: Harvard University Program in Ethics and Health annual and other conferences.

MAIN COMMITTEE SERVICE POSITIONS (the full CV lists many others)

- 2021-pres. Chair, Search Committee for CPLB faculty, Rutgers U.
 2021-pres. Member, Search Committees for GHI faculty and for IFH Director, Rutgers U.
 2020-pres. Member, Association of Bioethics Program Directors
 2020-pres. Advisory Board Member, 1 Day Sooner
 2020-2022 Member, NJ Department of Health Professional Advisory Committee (PAC)
 2020-pres. Member, COVID-19 Testing Protocol Action Group (TPAG), Rutgers U.
 2020-pres. Member, Rutgers University Medical Cannabis Workgroup, Rutgers U.
 2020-2021. Member, Wellcome Trust advisory committee on human challenge trials for Coronavirus
 2020-2021. Member, RWJ-Barnabas Taskforce on health system response to Crisis Standards of Care during the COVID-19 crisis.
 2019-pres. Member, Rutgers University Microbial Protection (RUMP) advisory board.
 2015-2017 Member, Harvard TH Chan faculty advisory group that designed, runs the pilot for, a new MPH integrated core course.
 2014-pres. Chair, Subcommittee for Revising the Massachusetts draft guidelines on Emergency Preparedness,
Task Force on Ethical Aspects of Emergency Preparedness
 2014-2016 Member, International AIDS Society task force, “Towards an HIV cure”
 2013-2016 Chair, American Philosophical Association Committee on Philosophy and Medicine
 2013-2017 Chair, American Society for Bioethics & the Humanities *Philosophy* (since 2015: + *History*) Subcommittee
 2011-2019 Member, University Faculty Committee, EJ Safra Center for Ethics, Harvard University

EDITORIAL (the full CV lists additional editorial roles and ad-hoc refereeing for 54 journals).

- 2018-pres. International Editorial Board member, *Behavioral Applied Ethics* (Rowman and Littlefield)
 2015-pres. Board of Advisors member, *Oxford Studies in Political Philosophy*.
 2015-pres. Editorial Board member, *Public Health ethics*.
 2014-2021 Advisory board member, *Social Theory and Practice*.
 2013-pres. Editorial board member, *Applied Ethics* (Oxford UP).
 2013-pres. Editorial board member, *International J of Health Policy & Management*.
 2011-pres. Series co-editor, *Population-Level Bioethics*, Oxford UP, New York.
 2010-pres. Associate editor and book review editor (Bioethics), *Ethical Perspectives*.